Emil Chuang
Technik-/Wissenschafts-/F&E-Leiter bei Intrinsic Medicine, Inc.
Profil
Emil Chuang is currently the Chief Medical Officer at Intrinsic Medicine, Inc. He previously held the same position at the same company.
Prior to that, he was the Global Head-Translational Research at Takeda Pharmaceutical Co., Ltd.
from 2016 to 2018.
From 2018 to 2020, he was the Vice President-Precision Medicine at Biora Therapeutics, Inc. Chuang completed his undergraduate degree at The University of Sydney.
Aktive Positionen von Emil Chuang
| Unternehmen | Position | Beginn |
|---|---|---|
Intrinsic Medicine, Inc.
 Intrinsic Medicine, Inc. Miscellaneous Commercial ServicesCommercial Services Intrinsic Medicine, Inc. operates as a therapeutics company leveraging human milk biology to create new medicines to transform gut-brain axis (GBA) disorders with large populations underserved by current treatment options. The company was founded by Alexander Martinez and Jason Ferrone in August, 2018 and is headquartered in Seattle, WA. | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2021 |
Ehemalige bekannte Positionen von Emil Chuang
| Unternehmen | Position | Ende |
|---|---|---|
| BIORA THERAPEUTICS, INC. | Corporate Officer/Principal | 01.12.2020 |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Corporate Officer/Principal | 01.06.2018 |
Ausbildung von Emil Chuang
| The University of Sydney | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Health Technology |
| BIORA THERAPEUTICS, INC. | Health Services |
| Private Unternehmen | 1 |
|---|---|
Intrinsic Medicine, Inc.
Intrinsic Medicine, Inc. Miscellaneous Commercial ServicesCommercial Services Intrinsic Medicine, Inc. operates as a therapeutics company leveraging human milk biology to create new medicines to transform gut-brain axis (GBA) disorders with large populations underserved by current treatment options. The company was founded by Alexander Martinez and Jason Ferrone in August, 2018 and is headquartered in Seattle, WA. | Commercial Services |
